LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Stock List・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Closed

SectorHealthcare

21.12 -0.94

Buy Sell

Overview

Share price change

24h

Current

Min

21.02

Max

21.21

Key metrics
By Trading Economics
Income	-270M 3.6M
Sales	-16M 268M
P/E Sector Avg	9.362 49.701
EPS	0.02
Profit margin	1.357
Employees	796
EBITDA	-31M -4.6M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+51.99% upside

Dividends
By Dow Jones
Next Earnings	5 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-256M 3.5B
Previous open	22.06
Previous close	21.12

News Sentiment

By Acuity

50%

159 / 345 Healthcare

ACADIA Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

25 May 2026, 08:24 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 May 2026, 21:22 UTC

Earnings

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 May 2026, 20:50 UTC

Market Talk

Earnings

Basic Materials Roundup: Market Talk

25 May 2026, 16:20 UTC

Market Talk

Earnings

Basic Materials Roundup: Market Talk

25 May 2026, 16:01 UTC

Market Talk

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 May 2026, 14:43 UTC

Market Talk

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 May 2026, 14:15 UTC

Market Talk

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 May 2026, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25 May 2026, 12:58 UTC

Market Talk

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 May 2026, 12:56 UTC

Market Talk

Earnings

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 May 2026, 12:48 UTC

Market Talk

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 May 2026, 12:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25 May 2026, 12:34 UTC

Market Talk

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 May 2026, 12:10 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Delivery Hero's Assets Look Strategic -- Market Talk

25 May 2026, 11:00 UTC

Market Talk

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 May 2026, 10:19 UTC

Market Talk

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 May 2026, 10:05 UTC

Earnings

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 May 2026, 10:04 UTC

Earnings

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 May 2026, 10:03 UTC

Earnings

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 May 2026, 10:02 UTC

Earnings

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 May 2026, 10:01 UTC

Earnings

Tenaga Nasional 1Q Net Up 3.7% on Year

25 May 2026, 10:00 UTC

Earnings

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 May 2026, 09:56 UTC

Earnings

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 May 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q EPS MYR0.1883

25 May 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q Rev MYR17.1B

25 May 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q Net MYR1.1B

25 May 2026, 09:38 UTC

Market Talk

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 May 2026, 09:33 UTC

Market Talk

Global Equities Roundup: Market Talk

25 May 2026, 09:33 UTC

Market Talk

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 May 2026, 08:55 UTC

Market Talk

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Peer Comparison

Price change

ACADIA Pharmaceuticals Inc Forecast

Price Target

By TipRanks

51.99% upside

12 Months Forecast

Average 32.07 USD 51.99%

High 38 USD

Low 23 USD

Based on 16 Wall Street analysts offering 12 month price targets forACADIA Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

Buy

Hold

Sell

Based on 16 analysts giving stock ratings to ACADIA Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

159 / 345 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.